Brief: Replicel's phase 1 clinical trial for hair loss meets primary endpoints
14/03/2017 10:00
March 14 (Reuters) - Replicel Life Sciences Inc RP.V
* Replicel's phase 1 clinical trial for hair loss succeeds
in meeting primary endpoints
* Replicel life sciences - trial succesfully met its
endpoints and sets stage for next steps in ongoing research and
development of its product, rch-01
Source text for Eikon: ID:nPn919jr2a
Further company coverage: RP.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Replicel Life Sciences
See all newsBrief: Replicel Life Sciences Announces Reinstatement Of Trading & Conditional Acceptance For Proposed Transaction
Brief: Replicel Life Sciences Says Replicel Announces A Letter Of Intent For Asset Purchase Agreement
Brief: Replicel Announces Binding Term Sheet For Strategic Investment And U.S. Partnership
Brief: Replicel Announces Its Incoming Board Of Directors
Brief: RepliCel Life Sciences Retains Dermatology Sales And Marketing Executive To Guide Global Commercial Strategy For Automated Dermal Injector